Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Warfarin Pharmacogenetics Reevaluated: Subgroup Analysis Reveals a Likely Underestimation of the Maximum Pharmacogenetic Benefit by Clinical Trials.

American journal of clinical pathology - 1 May 2016

Stack Gary, Maurice Carleta B

Abstract excerpt

OBJECTIVES: Various patient subgroups were examined to determine which ones obtain the largest pharmacogenetic improvements in warfarin dose accuracy. Subgrouping schemes of recent clinical trials were analyzed for comparison. METHODS: The accuracy of a pharmacogenetic dose algorithm was determined retrospectively in comparison to that of a clinical algorithm in subgroups of the International Warfarin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Anticoagulants
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmacogenomic Testing

Share to Warfarin

Source

Identifiers

PMID: 27247371
DOI: 10.1093/ajcp/aqw049

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Warfarin Pharmacogenetics Reevaluated: Subgroup Analysis Reveals a Likely Underestimation of the Maximum Pharmacogenetic Benefit by Clinical Trials.PMID 27247371Read ↗

Warfarin pharmacogenetics: does more accurate dosing benefit patients?Semantic proximity Read ↗

Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.Semantic proximity Read ↗

Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups.Semantic proximity Read ↗

The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing.Semantic proximity Read ↗

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinSemantic proximity Read ↗

Integration of genetic, clinical, and INR data to refine warfarin dosing.Semantic proximity Read ↗

STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATION.Semantic proximity Read ↗

A pharmacogenetic versus a clinical algorithm for warfarin dosing.Semantic proximity Read ↗

Accuracy of the pharmacogenetic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort.Semantic proximity Read ↗

Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing.Semantic proximity Read ↗

Warfarin dosing algorithms: A systematic review.Semantic proximity Read ↗

Pharmacogenetic dose refinement prevents warfarin overdose in a patient who is highly warfarin-sensitive.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.